To understand the therapeutic potential of targeting these two pathways to treat PTX-resistant GC, we assessed the antitumor effects of PI3k/mTOR dual inhibitor BEZ235, mTOR inhibitor everolimus, and MEK inhibitor AZD6244 in paired HGC-27 cells. This evidence concerns the gene MTOR and gastric cancer.